Board of Directors

Mr. Jonas is the Founder and Chairman of IDT Corporation (NYSE: IDT), Genie Energy (NYSE: GNE), and IDW Media (OTC: IDWM). He was also the Founder and controlling shareholder of Straight Path Communications, Inc (NYSE: STRP), which was acquired by Verizon for $3.1 Billion. Mr. Jonas has extensive leadership experience in founding and growing public companies, and has sold multiple businesses in deals worth both hundreds of millions and billions of dollars. He received his B.A. in economics from Harvard University.

Shmuel Levinger has served on the board since May 2022. Mr. Levinger is currently completing his MD at Tel Aviv University. He serves as VP of insurance at IDT corporation and worked extensively on their business development team prior to his current appointment. Mr. Levinger works at Sheba Medical Center where he is researching the implementation of advanced technology in the medical sector. Mr. Levinger graduated with a BA in Biology _cum laude_ from Tel Aviv University.

Alan B. Rosenthal has served as a director of Genie Energy Ltd. since October 2011. Dr. Rosenthal is the founding and managing partner of ABR Capital Financial Group LLC, an investment fund, founding partner and owner of NorthStar Travel, founding partner of Alaska Business Monthly and founding partner and owner of Master Dental Alliance. Dr. Rosenthal is an assistant clinical professor of Micro-Neurosurgical Treatment of Oral Pathology at New York University. Dr. Rosenthal is a board member of Yeshiva University and served on the board of directors of IDT Corporation from 1994 through 1996. He has a Bachelor of Science degree from Rutgers University and a DMD degree from University of Pennsylvania.

Dr. Shorr has a 40-year track record in drug discovery from concept through approval and market launch. As Cornerstone’s Chief Scientific Officer, Dr. Shorr’s primary focus is on the discovery and development of safe and effective novel drugs and delivery technology. He has previously served as VP of Science and Technology at Enzon Pharma, VP of Science and Technology and Chief Scientist at United Therapeutics, and Associate Director of Molecular Pharmacology at SmithKline Beecham. At Enzon, Dr. Shorr was responsible for co-development with Schering-Plough of the blockbuster drug, PEG INTRON A, for the treatment of hepatitis and certain forms of melanoma. Dr. Shorr has authored more than 250 technical articles, abstracts, book chapters and conference proceedings and has more than 150 inventions with more than 300 issued and pending patents worldwide. He earned his Ph.D. from the University of London, and a DIC from the University of London Imperial College of Science and Technology.

Mr. Stern is the Founder and CEO of Eastern Properties, a commercial and residential real estate company located in Cranbury, NJ. He is well known for his commitment and involvement in education as well as other philanthropic causes.

Mr. Wilmerding is the Co-Founder of Althea Partners LLC, which consults with and invests in early stage companies. Althea Partners led the Series B-4 preferred investment round in Cornerstone (known as Cornerstone Pharmaceuticals, Inc. at the time). Prior to co-founding Althea Partners, Mr. Wilmerding was a Co-Founder and Director of the Narragansett Bay and Pawtucket Insurance Companies. He also currently serves as a Director of Irresistible Materials Ltd., a next generation nano materials company.